One of the first things on the Ontario Progressive Conservative agenda was to change OHIP+. Fundamentally the program will be the same, including who is covered and what is covered; however the government will now be 2nd payor instead of 1st payor. Individuals who...
Recent article published by the Benefits & Pension Monitor National pharmacare is no longer an if, but a when, says Chris Bonnett, principal consultant with H3 Consulting. Speaking at The Benefits Alliance Group 2018 AGM and Spring Conference ‘Climbing Higher,’ he...
In December 2017 the Canadian Leadership Council on Drug Plan Partnerships met to discuss how Private and Pharmacare can partner to share in the risks of a National Drug Program. Included in this meeting were our own Paul Crossdale, President MC&A and Kathleen...
Statement by Minister of Health and Long-Term Care January 29, 2018 The following statement was issued today by Dr. Eric Hoskins, Minister of Health and Long-Term Care, following an announcement by the pan-Canadian Pharmaceutical Alliance and the Canadian Generic...
Canada’s first major biosimilar drug appears to be having a rough start in the private group insurance industry. Meanwhile, it looks like much smoother sailing for public drug plans, which are going ahead with preferred listing status for Inflectra based on a price...
A Quebec employer recently boasted about its unconventional hiring policy – the company has never hired a “smoker” in its 30 years as a business, and its proud of this stance. News like this is mildly shocking in Canada, where the idea of health outcomes, personal...
